Status: 02/21/2021 10:31 a.m.
It is still unclear whether people vaccinated against Corona will be infected with the virus and then pass it on. Data from Israel suggests BioNTech’s vaccine significantly reduces virus transmission.
An Israeli study gives reason to hope that the corona vaccine from the German pharmaceutical company BioNTech and its US partner Pfizer will significantly reduce the transmission of the virus. The investigation comes from the Israeli Ministry of Health, which worked with Pfizer on it. It has not yet been published, but is available to several media – including the Reuters news agency and “Spiegel”.
Accordingly, the vaccine can prevent the transmission of Sars-Cov-2 to 89.4 percent, including asymptomatic cases. Symptomatic cases would be reduced by 93.7 percent. “ The se evaluations are of great importance. The y are the first clear indication that you are not infected and not contagious after vaccination,” said SPD health expert Karl Lauterbach of “Bild am Sonntag”.
Lauterbach had already pointed out the study in a tweet yesterday. If the numbers are confirmed, herd immunity would be possible through vaccination.
99 percent protection against serious illnesses
The Israeli Ministry of Health itself released data on the effectiveness of the vaccine against the risk of disease. Accordingly, after the second dose, the agent prevents 95.8 percent disease from Covid-19, 98 percent the occurrence of symptoms such as fever and breathing difficulties and about 99 percent hospital stays, serious illnesses and death. Previous analyzes had confirmed that the vaccine was 95 percent effective.
On Friday it was also announced that the vaccine was highly effective after the first dose. Just two to four weeks after the first injection, the effectiveness is 85 percent, according to a study published in the journal “ The Lancet”.
Pfizer and BioNTech also announced that the vaccine can be stored at higher temperatures than previously known. Even when stored at -25 to -15 ° C, the vaccine is stable, which enables the use of common pharmaceutical freezers and refrigerators. So far it is mandatory that the vaccine must be stored at temperatures between -80 ° C and -60 ° C.